<a href="https://www.fiercebiotech.com/biotech/intellia-races-vivo-crispr-therapy-fda-after-phase-3-data-paint-compelling-picture" hreflang="en">Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture</a>
Intellia Therapeutics has announced positive phase 3 trial results for its CRISPR-based gene-editing therapy, lonvoguran ziclumeran (lonvo-z), which significantly reduced swelling attacks in patients with hereditary angioedema, leading the company to initiate a rolling submission for FDA approval. The therapy demonstrated a compelling efficacy profile, with a one-time infusion resulting in an 87% reduction in attacks compared to placebo, positioning it as a potentially transformative treatment option in the market.
Intellia Therapeutics' phase 3 trial results for their in vivo CRISPR therapy, lonvoguran ziclumeran (lonvo-z), demonstrated a significant reduction in hereditary angioedema attacks, positioning it as a compelling one-time treatment option. With plans for an FDA rolling submission and a potential launch in 2027, the key challenge will be addressing safety concerns and persuading patients to adopt this gene-editing therapy over existing treatments. This development is a critical signal for investors and stakeholders in the healthtech and biotech domains to monitor, given the therapy's potential to disrupt the current HAE treatment market.